Results 31 to 40 of about 2,233,111 (188)

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China

Frontiers in Cardiovascular Medicine, 2023
BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo, Yao Lu, Fei Guo, Aihua Wu, Yuesong Weng   +4 more
doaj   +1 more source

Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI

Clinical and Applied Thrombosis/Hemostasis, 2022
Since aspirin and clopidogrel are the widely and conventionally used drugs to treat acute myocardial infarction after percutaneous coronary intervention (PCI), it is important to explore potential risk factors of their resistance.
Lijie Zhang PhD, MD, Ying Lv PhD, MD, Jianyu Dong PhD, MD, Nana Wang MSc, Zhan Zhan MSc, Yuan Zhao BSc, Shanshan Jiang PhD, MD   +6 more
doaj   +1 more source

Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)

Pharmacology Research & Perspectives, 2021
Clopidogrel resistance is an important risk factor of ischemic event recurrence after optimal antiplatelet therapy. This study aims to investigate the role of CYP2C19 gene DNA methylation as one of the epigenetic factors for the risk of clopidogrel ...
Renan Sukmawan, Erick Hoetama, Siska Suridanda Danny, Astuti Giantini, Erlin Listiyaningsih, Vidya Gilang Rejeki, Amir Aziz Alkatiri, Isman Firdaus   +7 more
doaj   +1 more source

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

BMC Cardiovascular Disorders, 2022
Backgrounds Remarkable interindividual variability in clopidogrel response is observed, genetic polymorphisms in P2RY12 and its signal pathway is supposed to affect clopidogrel response in CHD patients.
Yan-Jiao Zhang, Dong-Jie Li, Zhong-Yi Li, Xiao-Lei Hu, He Li, Qi-Lin Ma, Xiao-Ping Chen   +6 more
doaj   +1 more source

Drug interactions and hepatotoxicity of clopidogrel [PDF]

, 2010
Clopidogrel (Plavix¨) is an antiplatelet drug, which is clinically used in combination with aspirin to reduce cardiovascular events in patients undergoing percutaneous coronary intervention or in patients suffering from acute coronary syndromes ...
Zahno, Anja-Christina
core   +1 more source

Comparison of Light Transmission Aggregometry and VerifyNow in Detecting Clopidogrel Resistance and Factors Affecting Clopidogrel Resistance in AMI-EST Patients Undergoing Percutaneous Coronary Intervention: A Cross-Sectional Study [PDF]

, 2021
BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in ...
Sahar, Windy, Setiabudy, Rianto, Dharma, Rahajuningsih, Suparmin, Siskawati, Giantini, Astuti, Alwi, Idrus, Harahap, Alida Roswita, Timan, Ina Susianti, Listiyaningsih, Erlin, Indrasari, Nuri Dyah, Partakusuma, Lia Gardenia, Sukmawan, Renan   +11 more
core   +1 more source

The stent thrombosis in Belgium (STIB) scoring system reliability in Indonesia patients and the modified STIB scoring (M-STIB)

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023
Introduction Clopidogrel is recommended as an alternative to Acetyl Salicylic Acid (ASA), the first-line drug for secondary stroke prevention. Clopidogrel resistance in Indonesia is reportedly 15.8%.
Rakhmad Hidayat, Al Rasyid, Salim Harris, Alida R. Harahap, Herqutanto, Melva Louisa, Erlin Listiyaningsih, Aldy Safruddin Rambe, Tonny Loho   +8 more
doaj   +1 more source

Drug resistance with monitored adherence [PDF]

, 2013
Drug resistance can be defined as the failure of a drug to exert its expected effect on pharmacological biomarkers and is caused by pharmacogenetic, cellular or clinical factors.
Walter, Philipp Niklaus
core   +1 more source

Clopidogrel Resistance

American Journal of Therapeutics, 2010
Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become the cornerstone of modern cardiovascular treatment. This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality.
Jaya Prakash, Sugunaraj, Chandrasekar, Palaniswamy, Dhana Rekha, Selvaraj, Sri Krishna, Chaitanya Arudra, Rishi, Sukhija   +4 more
openaire   +4 more sources

Clopidogrel Resistance in Ischemic Stroke Patients. [PDF]

Ann Indian Acad Neurol
Stroke remained the second leading cause of death globally in 2019. The antiplatelet drug clopidogrel is used to keep blood clots from forming in people who have experienced a stroke. Although most people find clopidogrel to be safe and beneficial, there is inevitably a range in how each patient responds.
Lavanya S, Babu D, Dheepthi D, Dhinakar E, Vivekanandh G.   +4 more
europepmc   +4 more sources